Ecolab: 94% Buy Ratings, but EPS Growth Trails Sales
Ecolab trades around $269.46 as I write this, 12.2% below its 52-week high of $307, and sixteen analysts covering the stock put 94% of their ratings at Buy. That is a lopsided consensus for a company whose most recent quarterly revenue grew 10% year over year. Consensus this one-sided usually means the market has already decided the stock deserves a premium multiple. Earnings tell a quieter story.
Ecolab sells water treatment, cleaning chemicals, pest control and hygiene products mostly to businesses that cannot skip them: hotels, hospitals, restaurants and food and beverage plants. It is a route business in the sense that once a customer signs on for a water-treatment or pest-control program, switching suppliers means requalifying equipment and retraining staff, which most operators avoid unless service slips. I made a similar point about recurring service contracts in my piece on Cintas’s uniform rental model, where the stickiness of the relationship matters more than any single price increase.
Where the revenue actually comes from
Effective January 2025, Ecolab renamed its former Global Industrial segment to Global Water and made Global Life Sciences a standalone reportable segment, according to the company’s fiscal 2025 annual report on SEC EDGAR. On a full-year 2025 basis, Global Water was roughly half of segment revenue, Global Institutional & Specialty around a third, Global Pest Elimination in the high single digits, and Global Life Sciences the smallest piece at under 5%. Water and Institutional & Specialty carry most of the growth story. Pest Elimination and Life Sciences move the total less on their own.
That mix matters because Global Water includes energy and heavy industrial customers whose spending ties to plant utilization, while Institutional & Specialty leans on foodservice and hospitality traffic. When one segment slows, the other has historically offset it, which is part of why Ecolab’s total revenue has stayed positive through periods when a single end market weakened.
Pest Elimination and Life Sciences are worth watching separately even though they are small. Life Sciences serves pharmaceutical and biotech manufacturing, a customer base with long qualification cycles. Once Ecolab’s water and cleaning systems are validated into a drug manufacturing process, replacing them requires re-validation that most plants avoid. That is a slower-growing, higher-margin niche, the kind of demand that does not move much with the economic cycle, which I made a related point about when I looked at Coca-Cola’s organic growth against its reputation.
The gap between revenue growth and profit growth
Full-year 2025 revenue came to $16.1 billion, up 2% from $15.7 billion the year before. The most recent quarter alone brought in $4.4 billion, up 10% year over year and 9% sequentially, putting the trailing run rate near $17.7 billion. That is a real acceleration versus the 2024 pace, and it is the number bulls point to first.
Net income for the year was $2.1 billion, a net margin of 13%, against $2.1 billion in the prior year. That is essentially flat. Operating income came to $2.9 billion, an operating margin of 18%, with gross margin at 44.5% versus 43.5% a year earlier. Gross margin did expand, which is the encouraging half of the picture. But it did not fully offset higher spending elsewhere, because net income barely moved while revenue rose 2%. I read that as costs, investment spending or one-time items absorbing the incremental sales dollar before it reaches shareholders. The company’s quarterly filings would show the exact mix. The aggregate figures alone do not say which line item is responsible, and I would not guess.
A specialty chemicals company like Ecolab buys resins, surfactants and packaging as raw material inputs. Those costs move with energy and commodity prices more than with anything Ecolab controls directly. Gross margin expanding to 44.5% suggests input costs eased or pricing held, but if operating margin still lags, the more likely explanation sits below the gross-profit line: SG&A, R&D or restructuring charges tied to the Life Sciences segment split I mentioned above. Investors get the segment-level detail only when Ecolab files its next 10-Q. Until then this stays a gap I can describe but not fully explain.
What the multiple is already pricing
At 36.2 times trailing earnings, Ecolab sits below its own five-year average of 41.7. The stock has actually been more expensive than this for most of the last five years. On a forward basis the multiple compresses to 32.4, implying the market expects earnings per share to grow roughly 12% from the trailing $7.45 to a forward estimate near $8.32. Price-to-sales tells a similar story: 4.6 now against a five-year average of 4.2 and a forward multiple of 4.1.
So the stock is not stretched relative to its own history, even with a Buy-heavy analyst base. Here is the risk, though. If the 12% forward EPS growth implied by the multiple does not show up, if margin pressure that held net income flat in 2025 persists into the next few quarters, a forward P/E of 32.4 stops looking like a discount and starts looking like a bet that has not paid off yet. That is my one explicit uncertainty here: I do not have enough in the segment data to know whether the margin drag is temporary input cost pressure or something structural in the newer Life Sciences and Pest Elimination units.
Where analysts and the market disagree
The average price target across the sixteen analysts I mentioned is $324, which is 20% above the current price, with targets ranging from $295 to $360. A 94% Buy rate alongside a spread that wide tells me analysts agree on direction. They do not agree on magnitude. The gap between the low and high target is nearly a quarter of the stock’s own price.
The stock’s own volatility profile backs up that uncertainty. Options pricing implies an average post-earnings move of 3.2%, and the last reported quarter, on 2026-07-28, moved the shares +4.2%. That is a modest reaction for a company this size, and it suggests the last print did not change anyone’s model by much. The market had already priced in decent revenue growth and was waiting on the margin story instead.
Ecolab also pays a trailing dividend of $2.84 per share, a yield of 1.05% at the current price. It is a small yield. What it signals matters more than its size: a mature, cash-generative business that is not leaning on the balance sheet to fund growth.
Two signals pointing in different directions
Short interest sits at 1.7% of the float. That is low. It means few traders are willing to bet against a steady, dividend-paying compounder, and it is one vote of confidence, though a small one. It does not mean the valuation debate is settled.
More interesting is the quant read. Ecolab’s underlying quant grade moved from C to D, a downgrade over the period I am looking at. Quant scores like this typically blend momentum, earnings revisions and valuation trend into one letter, so a slide from C to D while the stock still trades below its own five-year P/E average is a genuine tension, not noise. It lines up with the flat net income I described above. The price has not re-rated much. The underlying quality signal has softened anyway, and that deserves more attention than the headline Buy percentage gets it.
Book value backs up the same picture from a different angle. Price-to-book now sits at 7.7, just above the five-year average of 7.6. Investors are paying close to what they always have for each dollar of Ecolab’s equity, which is consistent with a stock that is fairly priced against its own history rather than obviously cheap or expensive.
| Metric | Current | Five-year average | Context |
|---|---|---|---|
| Trailing P/E | 36.2 | 41.7 | below own average despite 94% Buy ratings |
| Forward P/E | 32.4 | n/a | implies about 12% EPS growth |
| Price-to-sales | 4.6 | 4.2 | roughly in line |
| Price-to-book | 7.7 | 7.6 | roughly in line |
| Net margin | 13% | n/a | flat versus prior year |
| Quant grade | D | was C | downgraded over the period |
Nothing in that table screams overvalued. Nothing screams cheap either.
The number that would change my view
What I want before paying 36.2 times earnings for Ecolab is two consecutive quarters where net income growth closes the gap with revenue growth, not just gross margin expansion that gets absorbed elsewhere. If operating margin moves back above the 18% level and holds, the 32.4 forward multiple starts to look cheap rather than optimistic. If net income stays roughly flat while revenue keeps growing in the high single digits, the 94% Buy consensus will eventually have to explain itself, because a premium multiple funded entirely by top-line growth and none of it reaching shareholders is not a story that survives more than a few quarters.
I would treat the next earnings report as the test, whenever Ecolab discloses the date. Watch operating margin specifically, not the revenue headline that will almost certainly beat the prior year again. A business this defensive rarely misses on the top line; what it has not yet proven, on these numbers, is that a dollar of new revenue reliably becomes a dollar of new profit. Until it does, I would treat the 94% Buy rate as a bet on the story finishing, not evidence that it already has.
Analysis and opinion only, not investment advice. Figures come from Ecolab’s filings on SEC EDGAR and its investor site; segment mix is drawn from Ecolab’s fiscal 2025 annual report, and valuation multiples are approximate and were checked on September 22, 2026.
Sources: Dividends (SEC Investor.gov glossary) (https://www.investor.gov/introduction-investing/investing-basics/glossary/dividend) · Dividends tax topic (IRS) (https://www.irs.gov/taxtopics/tc404)